4D Molecular Therapeutics (NASDAQ:FDMT) Given Sell (E+) Rating at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a report released on Saturday morning,Weiss Ratings reports.

Several other research firms also recently weighed in on FDMT. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. Morgan Stanley lowered their price target on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a report on Monday, January 13th. Royal Bank of Canada lowered their price target on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. Bank of America lowered their price target on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating for the company in a report on Monday, March 10th. Finally, Chardan Capital lowered their price target on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, 4D Molecular Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $30.63.

4D Molecular Therapeutics Trading Up 4.5 %

NASDAQ:FDMT opened at $3.92 on Friday. The firm has a 50-day moving average price of $4.69 and a two-hundred day moving average price of $7.39. 4D Molecular Therapeutics has a twelve month low of $3.58 and a twelve month high of $36.25. The company has a market capitalization of $181.50 million, a P/E ratio of -1.38 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10). On average, equities research analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. KLP Kapitalforvaltning AS acquired a new position in 4D Molecular Therapeutics during the fourth quarter valued at approximately $48,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in 4D Molecular Therapeutics during the fourth quarter valued at approximately $50,000. PNC Financial Services Group Inc. lifted its position in 4D Molecular Therapeutics by 66.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after buying an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in 4D Molecular Therapeutics by 5,291.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock valued at $55,000 after buying an additional 9,737 shares in the last quarter. Finally, Velan Capital Investment Management LP acquired a new position in 4D Molecular Therapeutics during the fourth quarter valued at approximately $56,000. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.